Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-02-28FDA Approved: CYTARABINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approves Meitheal Pharmaceuticals' original application for CYTARABINE (cytarabine) as a generic injectable product, enabling its ma…
-
FDA approval · 2022-02-18FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for BLINCYTO (blinatumomab) submitted by Amgen, Inc.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial evaluating ponatinib in combination with chemotherapy for young adults with Philadelphia chromosome-positive acute ly…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [Phase 3]
Phase 3 clinical trial update for Total Therapy Study XVI in newly diagnosed acute lymphoblastic leukemia, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia [Phase 2, Phase 3]
Phase 2/3 clinical trial update for GRASPA (erythrocyte-encapsulated L-asparaginase) in relapsed acute lymphoblastic leukemia; results have …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) [Phase 4]
A Phase 4 trial update for treating Philadelphia-negative acute lymphoblastic leukemia in elderly patients (>55) is in an unknown status.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years [Phase 4]
A Phase 4 clinical trial update for frail, Philadelphia-negative patients over 55 with acute lymphoblastic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD [Phase 4]
A Phase 4 clinical trial evaluating the efficacy of bortezomib for relapsed acute lymphoblastic leukemia and related chemotherapeutic toxici…
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia [Phase 4]
Phase 4 trial evaluating the effect of simvastatin on sepsis and febrile neutropenia in patients with acute lymphoblastic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial evaluating feasibility and effectiveness of inotuzumab ozogamicin in B-cell acute lymphoblastic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy [Phase 4]
Phase 4 clinical trial comparing nalbuphine to ketamine for prevention of emergence agitation after sevoflurane in children undergoing tonsi…
-
FDA approval · 2022-01-03FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for dasatinib (DASATINIB) filed by Apotex Corp. The action confirms regulatory approval related to t…
-
FDA approval · 2021-12-21FDA Approved: ASPARLAS — Supplemental Application (Servier Pharmaceuticals LLC)
The FDA approved a supplemental application for ASPARLAS (calaspargase pegol) from Servier Pharmaceuticals LLC, indicating an approved updat…
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: Double Cord Versus Haploidentical (BMT CTN 1101) [Phase 3]
Phase 3 trial comparing double cord blood transplantation versus haploidentical transplant in acute leukemias completed with posted results.
-
FDA approval · 2021-11-23FDA Approved: DASATINIB — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s generic dasatinib (DASATINIB) under an Original Application (ANDA) for use in Philadelphia chromosome–positive l…
-
FDA approval · 2021-11-02FDA Approved: ONCASPAR — Supplemental Application (Servier Pharmaceuticals LLC)
The FDA approved a supplemental application for ONCASPAR (pegaspargase) filed by Servier Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement [Phase 2]
Phase 2 trial evaluating azacitidine with combination chemotherapy in infants with KMT2A-rearranged acute lymphoblastic leukemia and related…
-
FDA approval · 2021-10-25FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc. (ANDA089342).
-
FDA approval · 2021-10-25FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc., enabling a new generic version of the drug.
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia [Phase 2]
Phase 2 trial update on a targeted therapy for relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia; trial status ter…
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft [Phase 2, Phase 3]
Phase 2/Phase 3 evaluation of a donor testing kit to predict acute graft-versus-host disease in patients receiving peripheral blood stem cel…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL [Phase 3]
Phase 3 trial for Marqibo in adults 60+ with newly diagnosed acute lymphoblastic leukemia was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia [Phase 2]
An extension Phase 2 trial evaluating the safety and anti-leukemic effects of imatinib mesylate in adults with Ph+ leukemias has completed a…
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: Phase III B in Acute Lymphoblastic Leukemia [Phase 3]
Phase III trial in Acute Lymphoblastic Leukemia completed with results posted in 2021.
-
FDA approval · 2021-07-15FDA Approved: RYLAZE — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA entry describes a supplemental application for RYLAZE (asparaginase Erwinia chrysanthemi recombinant) submitted by Jazz Pharmaceutic…